Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

mpany's balance sheet at December 31, 2008, and had no impact to the Company's business operations, existing capital resources, or the Company's ability to fund its operating needs, including the development of its product candidates. The revisions, and a description of the basis for the revisions, are more fully described in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

This news release discusses historical information and includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including Regener
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... At the American Association of Neurological Surgeons ... D.C. , Elekta will highlight Leksell Gamma ... leverage the enormous amount of data – generated by ... – to advance clinical research and further optimize patient ... solution that allows practitioners to store, retrieve, and analyze ...
(Date:5/1/2015)... 2015 Pharmacyclics, Inc. (the "Company") (NASDAQ: ... ended March 31, 2015, as well as general business ... conference call will be held. Key Highlights ... 31, 2015 increased to $206 million from $119 million ... Worldwide IMBRUVICA ® (ibrutinib) net product revenue of ...
(Date:5/1/2015)... -- Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Sales increased 18% compared to the ... impact, driven by Innovator products and Controlled Substances. , ... first quarter of 2014. , GAAP Diluted EPS from ... last year and Adjusted Diluted EPS was $0.29 compared to ...
Breaking Medicine Technology:Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33Cambrex Reports First Quarter 2015 Financial Results 2
... today announced that the United States Food and ... Drug application (IND) to commence clinical trials advancing ... acute breakthrough seizures.   Following initial pre-IND discussions with ... based upon the encouraging human pharmacokinetic results seen ...
... 2012  Genomic Health, Inc. (Nasdaq: GHDX ) today ... goal of improving the quality of diagnosis, communication and support ... and rare genetic conditions.   The subsidiary is expected to be ... service in 2013.  The new venture will be led by ...
Cached Medicine Technology:Neurelis Announces FDA Allowance of IND Application for NRL-1, a Novel Intranasal Diazepam Formulation 2Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4
(Date:5/3/2015)... " Bubbly Walrus ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... games to play on smartphones are the ones that get ... with a video game that just absorbs attention, why not ...
(Date:5/3/2015)... Mateo, CA (PRWEB) May 03, 2015 ... service, MnemeTherapy® at two upcoming area seminars. The first ... the PSA Annual Regional Stroke Conference to be held ... be offered on Wednesday, May 13 during the Dementia ... Plaza. , “These seminars offer an excellent opportunity ...
(Date:5/2/2015)... As one of only 30 Illinois ... and Health Achievement and Recognition Program (SHARP) certification, ... by the Illinois Department of Labor to host this ... SHARP certification by the Occupational Safety and Health Administration’s ... continued to meet or exceed all of the necessary ...
(Date:5/2/2015)... 02, 2015 ProText Kinetic 2 is a ... Final Cut Pro X. ProText Kinetic 2 features 40 ... Final Cut Pro X . Easily create interactive text ... Film Studios' ProText Kinetic 2. , Using ProText Kinetic is ... two ProText Kinetic presets in the FCPX timeline. Playback ...
(Date:5/2/2015)... Ohio (PRWEB) May 02, 2015 On ... Liverpool City Hospital (ELCH) gathered to celebrate improvements in ... River Valley Health Partners (RVHP), had zero acquired ventilator ... urinary catheter associated infections. ELCH was also recently named ... The management team at ELCH credited the teamwork of ...
Breaking Medicine News(10 mins):Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... Findability with Flexibility of Vivisimo,s Velocity Search Platform , ... a powerful new level of social and personalized search for ... is helping the leading UK medical website expand its offerings ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20080626/NEW046LOGO ) , ...
... MOINES, Iowa, Nov. 24 Vitech Systems Group, Inc. ... Administration System Implementation at the Iowa Public Employees, Retirement ... funds in the U.S., contracted with Vitech in 2006 ... The solution provides advanced capabilities and increases efficiency, transforming ...
... Calif. Nov. 24, 2008Researchers at the University of Southern ... for aggressive prostate cancer blocks the development of prostate ... study in the Proceedings of the National Academy ... cancer therapy for humans. , "This research has ...
... has directed KH Real Estate to issue a boil water advisory ... Township, Armstrong County, after samples taken by DEP tested positive for ... DEP received complaints from residents after two customers were hospitalized with ... testing for the bacteria. , ...
... system for advanced radiation therapy, today announced that Rafael (Ralph) Vaello ... December 1, 2008. Mr. Vaello, who will report to TomoTherapy CEO ... sales and field marketing group for Philips Healthcare’s Oncology Imaging division. ... ...
... million of them currently abstain from alcohol, drugs , , ... million Americans over the age of 12 participate in ... including 2.3 million who currently abstain from use of ... released Monday by the federal Substance Abuse and Mental ...
Cached Medicine News:Health News:Vivisimo Helps OnMedica Deliver Personalized Search and Extend Social Search to Public-Facing Health Portal 2Health News:Vivisimo Helps OnMedica Deliver Personalized Search and Extend Social Search to Public-Facing Health Portal 3Health News:Vitech's V3 Pension Administration Software Improves IPERS' Business 2Health News:USC researchers identify novel approach for suppressing prostate cancer development 2Health News:Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory 2Health News: TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries 2Health News:5 Million People a Year Use Self-Help Addiction Programs 2
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
A.I.med's medical billing software is a medical billing software. The billing module integrates with A.I.med's Electronic Medical Record software. A.I.med's medical billing module also integrates wit...
... Medical Billing system allows a practice ... It is integrated with the EMR, ... system interfaces with electronic clearinghouses for ... a set of reports, it presents ...
... Infinity Amylase EPS single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... InfinityTM Amylase EPS reagent provides a ...
Medicine Products: